Berlin - Delayed Quote EUR

Faron Pharmaceuticals Oy (4FR.BE)

Compare
2.1900
-0.0200
(-0.90%)
As of 12:56:05 PM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
28,567.0000
28,567.0000
27,426.0000
21,109.0000
16,654.0000
Operating Income
-28,567.0000
-28,567.0000
-27,426.0000
-21,109.0000
-16,654.0000
Net Non Operating Interest Income Expense
-2,383.0000
-2,383.0000
-1,349.0000
-230.0000
-53.0000
Pretax Income
-30,944.0000
-30,944.0000
-28,730.0000
-21,178.0000
-16,934.0000
Tax Provision
--
--
--
16.0000
10.0000
Net Income Common Stockholders
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Diluted NI Available to Com Stockholders
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Basic EPS
-0.48
-0.48
-0.52
-0.42
-0.37
Diluted EPS
-0.48
-0.48
-0.52
-0.42
-0.37
Basic Average Shares
65,055.0360
65,055.0360
55,229.8350
50,723.9640
45,712.1110
Diluted Average Shares
65,055.0360
65,055.0360
55,229.8350
50,723.9640
45,712.1110
Total Operating Income as Reported
-28,568.0000
-28,568.0000
-27,426.0000
-21,108.0000
-16,654.0000
Rent Expense Supplemental
320.0000
320.0000
114.0000
7.0000
--
Total Expenses
28,567.0000
28,567.0000
27,426.0000
21,109.0000
16,654.0000
Net Income from Continuing & Discontinued Operation
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Normalized Income
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Interest Income
230.0000
230.0000
11.0000
2.0000
109.0000
Interest Expense
2,167.0000
2,167.0000
1,373.0000
215.0000
149.0000
Net Interest Income
-2,383.0000
-2,383.0000
-1,349.0000
-230.0000
-53.0000
EBIT
-28,777.0000
-28,777.0000
-27,357.0000
-20,963.0000
-16,785.0000
EBITDA
-28,431.0000
-28,431.0000
-27,057.0000
-20,657.0000
-16,502.0000
Reconciled Depreciation
346.0000
346.0000
300.0000
306.0000
283.0000
Net Income from Continuing Operation Net Minority Interest
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Normalized EBITDA
-28,431.0000
-28,431.0000
-27,057.0000
-20,657.0000
-16,502.0000
Tax Rate for Calcs
--
--
--
0.0002
0.0002
12/31/2020 - 1/21/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CVAC.VI CureVac N.V.
3.6080
-3.84%
 
BT3.BE Lineage Cell Therapeutics Inc
0.5850
0.00%
 
1GDA.F Zevra Therapeutics, Inc.
7.40
-3.27%
 
471A.F aTyr Pharma, Inc.
3.4200
+1.18%
 
HQ1.MU Oruka Therapeutics Inc. R
11.80
-3.28%
 
2Q5.BE Enochian BioSciences Inc
0.8460
-0.24%
 
ORN.F Oryzon Genomics S.A.
1.4660
+3.97%
 
PH4.F CStone Pharmaceuticals
0.2860
0.00%
 
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.4700
-3.09%
 
25I.F ImmuPharma plc
0.0605
+447.06%